H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT)

Cogent Biosciences, Inc. (NASDAQ:COGT) is among the 20 Best Performing Stocks in 2025.

Based on a research note dated January 6, 2026, The Fly reported that H.C. Wainwright reaffirmed a Buy rating and lifted its price target for Cogent Biosciences, Inc. (NASDAQ:COGT) from $50 to $52. The firm stated that it anticipated an uneventful FDA review procedure for bezuclastinib in cases of non-advanced systemic mastocytosis.

Cogent Biosciences, Inc. (NASDAQ:COGT) filed a New Drug Application for bezuclastinib in NonAdvanced Systemic Mastocytosis with the US Food and Drug Administration on December 30, 2025. This submission comes after the Breakthrough Therapy Designation for bezuclastinib in patients with smoldering systemic mastocytosis and NonAdvSM patients who were previously treated with avapritinib. It is based on favorable clinical data from the SUMMIT pivotal trial. All of the major and important secondary outcomes of the SUMMIT study were statistically significant. Bezuclastinib exhibited a therapeutic effect in every symptom domain, including improvements in the most severe baseline symptom as well as 11 patient-specific symptoms. Improvements in symptoms were associated with decreases in serum tryptase. Updated 48-week data revealed that the improvement in symptoms continued to deepen with time. Bezuclastinib showed a profile of safety.

Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology business that specializes in creating precision treatments for diseases that are determined by genetics.

While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None